• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.01%

    Rexahn Pharmaceuticals, Inc. (RNN)

    -NYSE MKT
    0.54 Up 0.02(3.79%) Jul 31, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Rexahn Pharmaceuticals, Inc.
    15245 Shady Grove Road
    Suite 455
    Rockville, MD 20850
    United States - Map
    Phone: 240-268-5300
    Fax: 240-268-5310
    Website: http://www.rexahn.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:22

    Business Summary 

    Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer and other medical needs. The company has three clinical stage oncology candidates: Archexin, RX-3117, and Supinoxin (RX-5902), as well as a pipeline of preclinical compounds to treat multiple types of cancer. It has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Rexahn Pharmaceuticals, Inc.

    Key Executives 
     PayExercised
    Dr. Peter D. Suzdak Ph.D., 56
    Chief Exec. Officer and Director
    531.00K0.00
    Dr. Chang H. Ahn Ph.D., 63
    Founder, Chairman Emeritus and Chief Scientist
    N/AN/A
    Dr. Tae Heum Jeong D. Mgt., 44
    Chief Financial Officer, Sr. VP and Sec.
    350.00K0.00
    Dr. Ely Benaim M.D., 54
    Chief Medical Officer
    N/AN/A
    Dr. Madhukar H. Trivedi M.D.,
    Consultant
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders